Cytokinetics Reports Results from the P-III (SEQUOIA-HCM) Study of Aficamten for Obstructive Hypertrophic Cardiomyopathy
Shots:
- The P-III (SEQUOIA-HCM) study investigates the safety, efficacy, and quantitative understanding of obstruction impact of aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy (HCM)
- The results revealed that aficamten improved exercise capacity vs PBO and increased the peak oxygen uptake (pVO2) by a least square mean difference of 1.74 (1.04 - 2.44) mL/kg/min
- Furthermore, improvements were also seen in 10 2EPs incl. Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), NYHA functional class improvement, change in provoked LVOT-G, proportion with LVOT-G <30 mmHg at wks. 12 & 24, exercise workload, and guideline-eligibility for septal reduction therapy
Ref: Cytokinetics | Image: Cytokinetics
Related News:- Cytokinetics Initiates P-III (SEQUOIA-HCM) Trial of Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
